(firstQuint)GliaSite 1-3 Mets Study.

 Data relevant to the evaluation the effectiveness of the GliaSite RTS for a resected dominant brain metastases will be collected.

 The GliaSite RTS is a radionuclide applicator and liquid radionuclide (Iotrex) designed to deliver intracavitary radiation therapy for resected brain tumors.

 In this case, it will irradiate the resected margins.

 Brain metastases not surgically removed will be then treated with radiosurgery.

 GliaSite 1-3 Mets Study@highlight

This study has been designed to compile information on the efficacy of the GliaSite RTS combined with radiosurgery in the treatment of newly diagnosed metastatic brain tumors.

